bioRxiv Science⌕ Search

Biology subjects

Kortulewski, T.

Publications and source records attributed to Kortulewski, T..

2 recordsLinked to original sources

Advanced human cerebral organoids as a model for investigating glioma stem cell interactions with microglia and vascular cells and response to radiotherapy

The recent development of human brain organoids from induced pluripotent stem cells (IPSCs) enables the modeling of brain biology and pathophysiology, such as gliomas. However, most models lack vascular and/or immune systems, both of which play essential roles in maintaining brain health and in pathophysiological mechanisms. We have established a new method for generating vascularized complex cerebral organoids (CCOs) containing microglial cells (brain-resident macrophages) by incorporating bipotent hematopoietic/endothelial progenitors derived from the same IPSC lines during the early stages of development. This approach led to the formation of extensive vascular-like structures with blood-brain barrier characteristics, which were perfused upon transplantation into immunodeficient mice. Additionally, microglial cells exhibiting typical phenotypes and functionalities also developed within the CCOs. By coculturing CCOs with glioma stem cells, we demonstrated that this model effectively recapitulates the tumor niche of glioblastoma, showing vascular co-option, reprogramming of microglia into tumor-associated macrophages, and recurrence after radiotherapy. In conclusion, our vascularized and immunocompetent CCO model will be invaluable for understanding human brain development, exploring how this process is disrupted in diseases like gliomas, and discovering new therapeutic strategies.

cancer biology↗

Loss of CD24 promotes radiation- and chemo-resistance by inducing stemness properties associated with a hybrid E/M state in breast cancer cells

There is compelling evidence that cancer stem cells (CSCs) play an essential role in failure of conventional antitumor therapy. In breast cancer, CD24-/low/CD44+ phenotype as well as a high aldehyde dehydrogenase activity (ALDH+) are widely associated with CSC subtypes. Furthermore, CD24-/low/CD44+ pattern is also characteristic of the mesenchymal cells generated by an epithelial-mesenchymal transition (EMT). CD24 is a surface marker expressed in many tumor types, however, its biological functions and role in cancer progression and treatment resistance remain poorly documented. We have previously shown that loss of CD24 expression in breast cancer cells is associated with radiation resistance, in relationship with the control of oxidative stress. Because ROS are known to mediate the effects of anticancer drugs as well as ionizing radiation, we investigated if CD24 could be defined as an actor of both radiation- and chemo-resistance of breast cancer cells. Using the HMLE breast cancer cell model, we observed that loss of CD24 expression induces stemness properties associated with the acquisition of a hybrid E/M phenotype. The CD24-/low cells were intrinsically more resistant than CD24+ cells. The resistance was linked to a lower level of ROS, and CD24 controlled ROS levels through the regulation of mitochondrial functions independently of antioxidant activity. Together, these results suggest a key role of CD24 in de-differentiation process of breast cancer cells, promoting acquisition of therapeutic resistance properties.

cancer biology↗